Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Gross Profit (2016)

Viridian Therapeutics, Inc.\DE has reported Gross Profit over the past 3 years, most recently at -$183000.0 for Q4 2016.

  • Quarterly results put Gross Profit at -$183000.0 for Q4 2016, down 190.15% from a year ago — trailing twelve months through Dec 2016 was $1.0 million (up 1441.18% YoY), and the annual figure for FY2016 was $929000.0, up 1307.58%.
  • Gross Profit for Q4 2016 was -$183000.0 at Viridian Therapeutics, Inc.\DE, down from $337000.0 in the prior quarter.
  • Over the last five years, Gross Profit for VRDN hit a ceiling of $1.2 million in Q2 2014 and a floor of -$2.4 million in Q4 2014.
  • Median Gross Profit over the past 3 years was $270000.0 (2015), compared with a mean of $149916.7.
  • Peak annual rise in Gross Profit hit 769.64% in 2016, while the deepest fall reached 190.15% in 2016.
  • Viridian Therapeutics, Inc.\DE's Gross Profit stood at -$2.4 million in 2014, then soared by 108.42% to $203000.0 in 2015, then tumbled by 190.15% to -$183000.0 in 2016.
  • The last three reported values for Gross Profit were -$183000.0 (Q4 2016), $337000.0 (Q3 2016), and $487000.0 (Q2 2016) per Business Quant data.